2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

4:30PM-6:00PM: Abstract Number: 2147

The Effect of Sulfasalazine and Methotrexate on the Immunogenicity of Infliximab and Adalimumab in Patients with Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment:Treatment of PsA and SpA

4:30PM-6:00PM: Abstract Number: 2128

The Role of Insulin Resistance in the Development of Premature Atherosclerosis in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA

4:30PM-6:00PM: Abstract Number: 2160

The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study

Vasculitis II

4:30PM-6:00PM: Abstract Number: 2168

The Smoking Paradox in the Development of Myocardial Infarction Among Rheumatoid Arthritis Patients

ARHP III: Epidemiology and Public Health

4:30PM-6:00PM: Abstract Number: 2150

Treatment with Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics I

4:30PM-6:00PM: Abstract Number: 2129

Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Abnormalities of Vascular and Myocardial Function on Cardiac MRI

Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA

4:30PM-6:00PM: Abstract Number: 2126

Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA

4:30PM-6:00PM: Abstract Number: 2161

Ustekinumab for the Treatment of Refractory Giant Cell Arteritis

Vasculitis II

4:30PM-6:00PM: Abstract Number: 2117

Weight Predicts Back Pain in Young Adult Women, Independent of Physical Activity: Data from the Australian Longitudinal Study on Women’s Health

Orthopedics, Low Back Pain and Rehabilitation

4:30PM-6:00PM: Abstract Number: 2166

Work Productivity in Newly Diagnosed, Untreated Rheumatoid Arthritis Patients

ACR/ARHP Combined Abstract Session: Epidemiology and Pubic Health

4:30PM-6:00PM: Abstract Number: 2131

Younger Age and Female Gender Are the Main Determinants of Underestimation of Cardiovascular Risk in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].